• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Indivior Agrees to Pay $385M Amid Monopoly Lawsuit


Wholesalers claim drugmaker illegally suppressed generic competition for opioid addiction treatment, Suboxone.

Wooden gavel and American dollars. Image Credit: Adobe Stock Images/domnitsky

Image Credit: Adobe Stock Images/domnitsky

Indivior, an addiction treatment company, announced that it has reached an agreement with wholesalers to resolve their claims of suppressing competition for its opioid addiction drug, Suboxone. As a result of the agreement, the upcoming trial, scheduled for Oct 30, has been cancelled. Reportedly, Indivior will pay $385 million and will take a charge of $228 million in the third quarter, which will be excluded from adjusted earnings.

“We are pleased to achieve this settlement to conclude this legacy multi-district antitrust matter,” said Mark Crossley, CEO, Indivior. “The resolution of this litigation, which was filed over a decade ago, provides greater certainty for all Indivior stakeholders and allows us to continue focusing on our important work for patients suffering from opioid use disorder and mental health illnesses around the world.”

Reference: Indivior Reaches Agreement with Direct Purchasers to Resolve Antitrust Multi-District Litigation; Provides Preliminary Q3 and YTD 2023 Results. Indivior. October 23, 2023. Accessed October 23, 2023. https://www.indivior.com/en/media/press-releases/Indivior-Reaches-Agreement-with-Direct-Purchasers-to-Resolve-Antitrust-Multi-District-Litigation-Provides-Preliminary-Q3-and-YTD-2023-Results

Related Videos
Related Content